Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELYM Eliem Therapeutics	$1.72 +5.5%	$1.40	$2.35 ▼ $11.55	$51.17M	-0.39	486,688 shs	404,398 shs
LIXT Lixte Biotechnology	$3.59 -7.9%	$2.84	$0.64 ▼ $5.14	$9.62M	0.43	871,120 shs	100,968 shs
PDSB PDS Biotechnology	$1.19 -0.8%	$1.33	$0.85 ▼ $4.29	$54.40M	0.95	541,415 shs	339,454 shs
UNCY Unicycive Therapeutics	$4.70 +1.5%	$5.28	$2.75 ▼ $11.00	$59.41M	1.88	359,606 shs	563,583 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELYM Eliem Therapeutics	+1.24%	-4.12%	+14.79%	+35.83%	-72.88%
LIXT Lixte Biotechnology	-3.94%	-20.08%	+5.12%	+182.61%	+85.71%
PDSB PDS Biotechnology	+3.45%	+7.14%	+2.56%	-15.49%	-60.26%
UNCY Unicycive Therapeutics	+4.99%	+14.04%	+0.22%	-22.30%	+46.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LIXT Lixte Biotechnology	0.1813 of 5 stars	0.0	2.0	0.0	0.0	1.8	0.8	0.0
PDSB PDS Biotechnology	2.035 of 5 stars	3.7	3.0	0.0	0.0	2.5	0.0	0.0
UNCY Unicycive Therapeutics	2.6381 of 5 stars	3.7	2.0	0.0	0.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELYM Eliem Therapeutics	0.00	N/A	N/A	N/A
LIXT Lixte Biotechnology	0.00	N/A	N/A	N/A
PDSB PDS Biotechnology	3.33	Buy	$9.00	656.30% Upside
UNCY Unicycive Therapeutics	3.33	Buy	$60.00	1,176.60% Upside

Current Analyst Ratings Breakdown

Latest LIXT, PDSB, UNCY, and ELYM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/11/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
5/27/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$90.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	$3.90 per share	N/A
LIXT Lixte Biotechnology	N/A	N/A	N/A	N/A	$0.24 per share	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	$0.51 per share	N/A
UNCY Unicycive Therapeutics	$680K	87.36	N/A	N/A	$0.72 per share	6.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELYM Eliem Therapeutics	-$35.12M	-$0.53	N/A	∞	N/A	N/A	-47.03%	-45.97%	N/A
LIXT Lixte Biotechnology	-$3.59M	-$1.29	N/A	∞	N/A	N/A	N/A	-222.90%	N/A
PDSB PDS Biotechnology	-$37.61M	-$0.94	N/A	N/A	N/A	N/A	-173.28%	-75.81%	N/A
UNCY Unicycive Therapeutics	-$36.73M	-$5.10	N/A	N/A	N/A	N/A	-277.30%	-61.53%	N/A

Latest LIXT, PDSB, UNCY, and ELYM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	UNCY Unicycive Therapeutics	-$0.70	-$0.52	+$0.18	-$0.52	N/A	N/A
8/13/2025	Q2 2025	PDSB PDS Biotechnology	-$0.24	-$0.21	+$0.03	-$0.21	N/A	N/A
8/7/2025	Q2 2025	LIXT Lixte Biotechnology	N/A	-$0.29	N/A	-$0.29	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A
LIXT Lixte Biotechnology	N/A	N/A	N/A	N/A	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELYM Eliem Therapeutics	N/A	60.41	60.41
LIXT Lixte Biotechnology	N/A	1.84	1.84
PDSB PDS Biotechnology	0.29	2.33	2.33
UNCY Unicycive Therapeutics	N/A	1.64	1.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELYM Eliem Therapeutics	69.76%
LIXT Lixte Biotechnology	5.10%
PDSB PDS Biotechnology	26.84%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
ELYM Eliem Therapeutics	4.70%
LIXT Lixte Biotechnology	14.80%
PDSB PDS Biotechnology	9.20%
UNCY Unicycive Therapeutics	10.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELYM Eliem Therapeutics	9	29.75 million	28.35 million	Not Optionable
LIXT Lixte Biotechnology	4	2.68 million	2.29 million	Not Optionable
PDSB PDS Biotechnology	20	45.71 million	41.51 million	Optionable
UNCY Unicycive Therapeutics	9	12.64 million	11.29 million	Not Optionable

LIXT, PDSB, UNCY, and ELYM Headlines

Recent News About These Companies

Unicycive Therapeutics reports Q2 EPS (52c), consensus (70c)

August 14 at 12:07 AM | msn.com

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

August 14 at 4:14 PM | gurufocus.com

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

August 14 at 3:55 PM | globenewswire.com

Unicycive Therapeutics requests Type A meeting with FDA to discuss CRL

August 14 at 2:05 PM | msn.com

Unicycive Therapeutics expects cash to fund operations into 2H of 2026

August 14 at 2:05 PM | msn.com

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

August 14 at 7:00 AM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 13 at 12:33 PM | globenewswire.com

Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Wednesday

August 12 at 8:43 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 11, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 9, 2025 | globenewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Holdings Lifted by Vivo Capital LLC

August 9, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 6, 2025 | prnewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Up 1,211.2% in July

August 3, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 31, 2025 | prnewswire.com

Unicycive Therapeutics Inc Ordinary Shares UNCY - Morningstar

July 30, 2025 | morningstar.comM

Unicycive Therapeutics (NASDAQ:UNCY) Trading Down 6.2% - Here's What Happened

July 30, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 28, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 27, 2025 | prnewswire.com

Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology

July 24, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 23, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 22, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIXT, PDSB, UNCY, and ELYM Company Descriptions

Eliem Therapeutics NASDAQ:ELYM

$1.72 +0.09 (+5.52%)

As of 08/14/2025

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Lixte Biotechnology NASDAQ:LIXT

$3.59 -0.31 (-7.95%)

Closing price 04:00 PM Eastern

Extended Trading

$3.61 +0.02 (+0.56%)

As of 05:16 PM Eastern

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

PDS Biotechnology NASDAQ:PDSB

$1.19 -0.01 (-0.83%)

Closing price 04:00 PM Eastern

Extended Trading

$1.22 +0.03 (+2.44%)

As of 06:03 PM Eastern

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

Unicycive Therapeutics NASDAQ:UNCY

$4.70 +0.07 (+1.51%)

Closing price 04:00 PM Eastern

Extended Trading

$4.75 +0.05 (+1.15%)

As of 06:28 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time